Want to see AU:GSS full AI Analyst Report?
Top Page
Genetic Signatures Ltd.
(Sydney:GSS)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.07
▼(-71.25% Downside)
Action:Upgraded
Date:08/26/26
The score is held down primarily by weak financial performance—deep negative margins, declining revenue, and multi-year negative operating/free cash flow—despite very low leverage. Technicals add some support from a short-term up-move (price above key short-term averages and positive MACD), but overbought readings and a weak longer-term trend temper that benefit. Valuation is also pressured by a negative P/E tied to ongoing losses, with no dividend yield provided.
Positive Factors
Proprietary diagnostic platform
The proprietary 3base® platform provides a foundation for differentiated multiplex molecular tests across gastrointestinal, respiratory, and other pathogen applications. A reusable technology platform can support product expansion and strengthen the company’s ability to serve multiple diagnostic workflows over time.
Negative Factors
Falling revenue and severe losses
Revenue contraction combined with deeply negative gross and net margins indicates that recent operations are not covering product costs and the fixed-cost base. Continued losses weaken earnings quality, reduce reinvestment capacity, and make a durable return to profitability dependent on substantial operating improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary diagnostic platform
The proprietary 3base® platform provides a foundation for differentiated multiplex molecular tests across gastrointestinal, respiratory, and other pathogen applications. A reusable technology platform can support product expansion and strengthen the company’s ability to serve multiple diagnostic workflows over time.
Read all positive factors
Genetic Signatures Ltd. (GSS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$17.94M
Dividend YieldN/A
Average Volume (3M)580.00K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue Growth-9.10%
EPS Growth31.75%
CountryAU
Employees117
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.06
Shares Outstanding227,138,820
10 Day Avg. Volume76,018
30 Day Avg. Volume580,005
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.43
Price to Sales (P/S)1.05
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$21.80M
Genetic Signatures Ltd. Business Overview & Revenue Model
Company Description
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of ...
How the Company Makes Money
GSS makes money primarily by selling molecular diagnostic test products to clinical laboratories, hospitals, and reference labs, generating revenue from (1) consumable assay sales and (2) instrument- and workflow-related product sales where applic...
Genetic Signatures Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.45M | 15.90M | 9.77M | 16.94M | 35.42M |
| Gross Profit | -12.72M | 7.78M | 4.31M | -12.74M | 7.21M |
| EBITDA | -15.68M | -16.08M | -19.82M | -13.14M | 4.70M |
| Net Income | -14.01M | -20.10M | -17.86M | -14.05M | 3.06M |
Balance Sheet | |||||
| Total Assets | 38.46M | 54.63M | 67.29M | 49.08M | 59.65M |
| Cash, Cash Equivalents and Short-Term Investments | 22.09M | 31.30M | 36.25M | 16.35M | 36.90M |
| Total Debt | 310.00K | 791.00K | 1.22M | 0.00 | 34.00K |
| Total Liabilities | 2.73M | 4.54M | 6.18M | 6.16M | 4.85M |
| Stockholders Equity | 35.72M | 50.09M | 61.10M | 42.91M | 54.80M |
Cash Flow | |||||
| Free Cash Flow | -8.82M | -13.19M | -14.91M | -20.55M | 6.82M |
| Operating Cash Flow | -7.77M | -12.29M | -10.12M | -12.45M | 9.81M |
| Investing Cash Flow | 9.85M | -24.30M | -4.79M | -8.09M | -2.99M |
| Financing Cash Flow | -481.00K | 7.79M | 34.81M | -23.00K | -101.00K |
Genetic Signatures Ltd. Technical Analysis
Negative
0.24
Price Trends
0.08
Negative
0.07
Positive
0.09
Negative
Market Momentum
<0.01
Positive
50.34
Neutral
38.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GSS, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and above the 200-day MA of 0.09, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.34 is Neutral, neither overbought nor oversold. The STOCH value of 38.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GSS.
Genetic Signatures Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$587.53M | 26.01 | 15.80% | 4.13% | -0.90% | -25.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$29.49M | -3.98 | -881.94% | ― | 743.51% | -1.52% | |
47 Neutral | AU$17.94M | -1.28 | -35.10% | ― | -9.10% | 31.75% | |
43 Neutral | AU$26.00M | -1.01 | -75.96% | ― | -5.81% | -3.60% | |
41 Neutral | AU$23.66M | -3.73 | -205.17% | ― | 239.64% | -37.21% |
* Healthcare Sector Average
AU:GSS
Genetic Signatures Ltd.
0.08
-0.26
-76.76%
AU:GTG
Genetic Technologies
―
―
―
AU:BDX
BCAL Diagnostics Limited
0.08
>-0.01
-11.11%
AU:RHY
Rhythm Biosciences Ltd.
0.07
-0.03
-30.11%
AU:ACL
Australian Clinical Labs Ltd
3.15
0.65
26.10%
AU:MAP
Microba Life Sciences Limited
0.04
-0.04
-53.95%
Genetic Signatures Ltd. Corporate Events
Genetic Signatures Faces Shareholder-Requested Vote on Director Removal
Sep 17, 2026
Genetic Signatures Ltd, a molecular diagnostics firm focused on PCR-based infectious disease testing for hospital and pathology laboratories, derives its core business from the 3base® platform and EasyScreen™ product suite.The company h...
Genetic Signatures Sets 2026 AGM Date and Director Nomination Deadline
Sep 14, 2026
Genetic Signatures Ltd has scheduled its 2026 Annual General Meeting for 16 November 2026, with the agenda to include the re-election of directors. The company has set 21 September 2026 as the deadline for shareholders or other parties to submit n...
Genetic Signatures Announces Departure of Director Caroline Waldron
Sep 1, 2026
Genetic Signatures Ltd has announced that non-executive director Caroline Waldron ceased to be a director of the company effective 31 August 2026. According to the notice lodged with the ASX, Waldron retains 22,514 fully paid ordinary shares and 2...
Mercer Investments Withdraws as Substantial Holder in Genetic Signatures
Aug 27, 2026
Mercer Investments (Australia) Limited, acting in various trustee and responsible entity capacities, has ceased to be a substantial shareholder in Genetic Signatures Ltd. as of 24 August 2026. The change reflects a reduction in Mercer’s voti...
Genetic Signatures in Early Merger Talks With Microba to Build Infectious Disease Diagnostics Group
Aug 26, 2026
Genetic Signatures Ltd has entered preliminary talks with fellow ASX-listed group Microba Life Sciences over a potential merger aimed at creating a leading infectious disease diagnostics player. The proposed combination would unite Genetic Signatu...
Genetic Signatures Files ASX Corporate Governance Statement for 2026
Aug 25, 2026
Genetic Signatures Ltd has lodged its annual corporate governance statement for the year ended 30 June 2026, confirming compliance with ASX requirements. The statement, approved by the board and accessible via the company’s website, outlines...
Genetic Signatures Tightens Losses and Restructures as Long-Term Deals Underpin Growth Plans
Aug 25, 2026
Genetic Signatures reported FY2026 revenue of $14.8 million, down 7% amid a competitive, price-sensitive market and a subdued respiratory testing season, but cut its net loss by 30% to $14.0 million and reduced operating cash outflows by 37% to $7...
Genetic Signatures Sets Date for FY2026 Results and Investor Briefing
Aug 24, 2026
Genetic Signatures Ltd., a global molecular diagnostics company, specialises in PCR-based EasyScreen assays built on its proprietary 3base platform to support high-volume hospitals and pathology laboratories in infectious disease screening. Its te...
Genetic Signatures Cuts Costs, Secures Danish Deal and Resets Global Growth Strategy
Jul 23, 2026
Genetic Signatures has completed an organisational restructuring that removes 30 roles, adds three project-focused positions and is expected to cut annual costs by about $5 million from FY2027, contributing to a leaner operating base. The move, to...
Genetic Signatures plays down BCAL stake, stresses business as usual
Jul 2, 2026
Genetic Signatures has responded to BCAL Diagnostics’ announcement that BCAL acquired shares in the company, clarifying it had no prior knowledge of the transaction and has received no communication about any strategic deal or corporate prop...
BCAL buys 10.2% stake in Genetic Signatures to broaden diagnostics platform
Jul 2, 2026
BCAL Diagnostics, an Australian healthcare company focused on early cancer detection, has taken a 10.2% stake in Genetic Signatures for $1.39 million in cash at $0.06 per share. Genetic Signatures’ infectious disease PCR platform and establi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.